Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro

Guncha Taneja,1 Chun Chu, Paramahamsa Maturu, Bhagavatula Moorthy, and Romi Ghose2

Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston (G.T., R.G.), and Department of Pediatrics, Baylor College of Medicine (C.C., P.M., B.M.), Houston, Texas

Received November 7, 2017; accepted February 1, 2018

ABSTRACT

Cytochrome P450 CYP3A4 is the most abundant drug-metabolizing enzyme and is responsible for the metabolism of ∼50% of clinically available drugs. Induction of CYP3A4 impacts the disposition of its substrates and leads to harmful clinical consequences, such as failure of therapy. To prevent such undesirable consequences, the molecular mechanisms of regulation of CYP3A4 need to be fully understood. CYP3A4 induction is regulated primarily by the xenobiotic nuclear receptor pregnane-X receptor (PXR). After ligand binding, PXR is translocated to the nucleus, where it binds to the CYP3A4 promoter and induces its gene expression. PXR function is modulated by phosphorylation(s) by multiple kinases. In this study, we determined the role of the c-Jun N-terminal kinase (JNK) in PXR-mediated induction of CYP3A4 enzyme in vitro. Human liver carcinoma cells (HepG2) were transfected with CYP3A4 luciferase and PXR plasmids, followed by treatment with JNK inhibitor (SP600125; SP) and PXR activators rifampicin (RIF) or hyperforin. Our results indicate that SP treatment significantly attenuated PXR-mediated induction of CYP3A4 reporter activity, as well as gene expression and enzyme activity. JNK knockdown by siRNA (targeting both JNK 1 and 2) also attenuated CYP3A4 induction by RIF. Interestingly, SP treatment attenuated JNK activation by RIF. Furthermore, treatment with RIF increased PXR nuclear levels and binding to the CYP3A4 promoter; SP attenuated these effects. This study shows that JNK is a novel mechanistic regulator of CYP3A4 induction by PXR.

This work was supported by National Institutes of Health [Grant R21DA035751-01A1 to R.G.], and [Grants R01 ES-019689, ES-001932, HL-129794, and HL-112516 to B.M.].

2Current affiliation: Primary Laboratory of Origin.

This work was previously presented as Taneja G, Chu C, Moorthy B, and Ghose R (2015) Regulation of human hepatic CYP3A4 expression: role of cytokines and MAP-kinases at 2015 American Association of Pharmaceutical Scientists annual meeting and exposition, Orlando, FL. https://doi.org/10.1124/dmd.117.079160.

Introduction

CYP3A4 enzyme is the most important contributor of hepatic and intestinal metabolism in adults (Krishna and Klotz, 1994; Guengerich, 1995; Leeder and Okey, 1996; Wilkinson, 2005). CYP3A4 is responsible for the metabolism of ∼50% of drugs currently used therapeutically for a wide spectrum of disorders, such as cancer, fungal and bacterial infections, neurologic disorders, hepatitis, AIDS, etc. (Guengerich, 1999; Veith et al., 2009; Zanger and Schwab, 2013). CYP3A4 also plays a crucial endogenous role in bile acid detoxification and metabolism of steroid hormones (Waxman et al., 1991; Araya and Wikvall, 1999).

Induction of CYP3A4 enzyme expression and activity alters the absorption, disposition, metabolism, and elimination of coadministered drugs (Thummel and Wilkinson, 1998). For example, supplementation with St. John’s wort significantly increases the clearance and decreases the mean area under the curve of the chemotherapeutic drug docetaxel (Goe et al., 2014). Similarly, a phase 1 trial showed that CYP3A4 induction by the chemotherapeutic compound bexarotene caused a 50% reduction in the area under the curve of atorvastatin, a lipid-lowering agent and CYP3A4 substrate (Wakelee et al., 2012). CYP3A4 induction is known to cause drug-drug interactions, failure of therapy, or drug toxicities in patients.

CYP3A4 gene is constitutively expressed by several liver-specific transcription factors, as well as by nuclear receptors, and is transcriptionally induced (Martínez-Jiménez et al., 2007). CYP3A4 induction is mediated by nuclear receptors (NRs) such as pregnane X receptor (PXR), constitutive androstane receptor, glucocorticoid receptor, and vitamin D receptor (VDR) (Pascussi et al., 2003; Luo et al., 2004). Among these NRs, PXR is primarily responsible for CYP3A4 induction (Goodwin et al., 2002, Xie et al., 2004). PXR provides an important mechanism for regulation needs to be fully elucidated to improve therapeutic outcome.

A growing body of evidence has shown that phosphorylation of PXR provides an important mechanism for CYP3A4 regulation.
(Staudinger et al., 2011). So far, PXR phosphorylation has shown a repressive effect on the transcription of its target genes. PXR phosphorylation by cyclic AMP-dependent protein kinase A represses CYP3A4 gene expression in a species-specific manner (Ding and Staudinger, 2005a; Lichti-Kaiser et al., 2009b). Similarly, cyclin-dependent kinase (Cdk2 and 5) phosphorylates PXR to inhibit CYP3A4 expression. PXR phosphorylation by Cdk2 at Ser350 inhibits CYP3A4 gene expression in HepG2 cells (Lin et al., 2008). Activation of protein kinase C by proinflammatory cytokines inhibits PXR transcriptional activity in hepatocytes (Ding and Staudinger, 2005b). Furthermore, PXR phosphorylation at Thr57 by p70 S6K inhibited PXR activity (Pondugula et al., 2009a). Although direct phosphorylation of PXR is not involved, recent studies showed that casein kinase 2-mediated phosphorylation of heat shock protein 90 stabilizes PXR and induces its downstream genes (Kim et al., 2015). Heat shock protein 90 is a cytoplasmic retention protein that binds to and sequesters PXR in the cytosol (Squires et al., 2004). Interestingly, the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK) was required for optimal activation of CYP3A4 gene by 1,25 dihydroxyvitamin D3 (1,25(OH)2D3), which is known to bind to and sequester PXR in the cytosol (Squires et al., 2004; Yasunami et al., 2004). MAPKs consist of two additional members, extracellular signal-regulated kinase (ERK 1/2) and p38 kinase (Zhou et al., 2009). These serine/threonine kinases transduce extracellular signals from activated receptors on the cell surface to cellular responses by phosphorylating transcriptional factors or downstream kinases (Houliston et al., 2001).

The goal of this investigation was to determine the mechanistic role of JNK in CYP3A4 induction by PXR in vitro. We observed that inhibition of JNK significantly attenuated PXR-mediated induction of CYP3A4 reporter activity, gene expression, and enzyme activity in HepG2 cells. We also confirmed that CYP3A4 enzyme activity was attenuated by treatment of HepRG cells with a JNK inhibitor. Furthermore, activation of JNK was observed upon treatment of HepG2 cells with the PXR ligand RIF. Interestingly, JNK inhibitors also attenuated ligand-induced PXR nuclear translocation and binding to the CYP3A4 promoter.

To date, PXR phosphorylation at multiple sites has inhibited PXR activity, leading to attenuation of CYP3A4 induction by PXR. To our knowledge, this is the first study showing that JNK is required for PXR-mediated CYP3A4 induction. This finding indicates that JNK may have a novel mechanistic role in CYP3A4 regulation by modulation of PXR function. These findings may provide insight into understanding functional interactions between cell signaling pathways and drug metabolism and their consequences in drug efficacy and/or toxicity.

Materials and Methods

Reagents and Materials. HepG2 cells were purchased from ATCC (Manassas, VA). HepaRG cells were purchased from Thermo Fisher Scientific (HPRGC10; Waltham, MA). RIF (3-4-methylpiperazinyliminomethyl) (R3501), hyperforin (dicyclohexylammonium) salt (C35H52O4N·HCl) (Sigma-Aldrich), and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). SP600125 (1, 9-pyrazolothiazole) (tibr-sp60), SB203580 (4-(1-(4-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenoxy)-1H-imidazol-5-yl)pyridine) (tibr-sh20), and PD098059 (2-2-amino-3-methoxyphenyl) chromen-4-one) (tibr-pd98) were purchased from InvivoGen (San Diego, CA). A custom siRNA sequence (AGAGA- GUCCUACCUUCCUUU) that simultaneously targets JNK1 and JNK2 and a control siRNA targeting luciferase were both synthesized by Dharmacon (Lafayette, CO). DharmaFECT Duo Transfection reagent was also purchased from Dharmacon.

HepaRG cells were maintained in Dulbecco’s modified Eagle’s medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA). Brieﬂy, cells were seeded in 96-well (2.0 × 10^4 cells/well), 24-well (8.0 × 10^4 cells/well), six-well format (4.0 × 10^5 cells/well), or six-well format (4.0 × 10^5 cells/well), depending on the type of assay at 80% confluency. After 24 hours, cells achieved 95% viability and were transfected with CYP3A4 luciferase (luc) promoter construct [contains the proximal promoter (−362/453) and distal XREM (−7836/−7208; inserted in pGL3 Basic vector) and h-PXR-spG5 plasmid together with the plRL-TK plasmid (which expresses Renilla luciferase) using SuperFect transfection reagent. For siRNA experiments, cotransfection of plasmids and siRNA was carried out with DharmaFect Duo reagent. A custom siRNA sequence targeting JNK 1 and JNK2 simultaneously and a control nontargeting siRNA were used for these experiments. HepG2 cells were transfected with JNK1/2 siRNA along with CYP3A4 luciferase and PXR plasmid using DharmaFect Duo reagent for 24 hours before treatment. HepaRG cells were cultured according to the manufacturer’s protocol. Cryopreserved cells were thawed with Williams’ E medium containing HepaRG thawing/plating medium. Cells were seeded in 96-well plates (100 μl/well) at a density of 0.1 million cells/ml. The cells recovered at 37°C with a 5% CO2 for 72 hours to achieve ~90% viability.

Measurement of Luciferase Reporter Gene Expression. After 24 hours of transfection, HepG2 cells were pretreated with 30 μM SP600125 (SP; specific JNK 1/2 inhibitor), 25 μM curcumin (JNK pathway inhibitor), 10 μM SB203580 (p-38 inhibitor), 25 μM PD098059 (ERK inhibitor), or DMSO (0.1%) as control for 30 minutes, followed by treatment with 1 μM hyperforin or 10 μM RIF or DMSO (0.1%) as control for 24 hours. After treatment, cells were lysed and Dual-Glo luciferase assay carried out according to manufacturer’s instructions (E1910; Promega). Brieﬂy, Dual-Glo luciferase buffer containing Dual-Glo luciferase substrate was added to the lysed cells, and luciferase activity was recorded. Firefly luciferase activity was normalized to Renilla luciferase activity and compared among different treatments.

Quantitative Real-Time Polymerase Chain Reaction. HepG2 cells were seeded in six-well plates at 80% confluency. After 24 hours, at ~95% viability, cells were pretreated with vehicle (0.1% DMSO) or 30 μM SP for 30 minutes, followed by 10 μM RIF for 0, 2, 4, 6, 8, and 12 hours. At each time point, total RNA was isolated using TRIzol reagent according to the manufacturer’s protocol (Sigma-Aldrich). cDNA was synthesized using the high-capacity reverse transcription kit from Applied Biosystems (Foster City, CA). Real-time polymerase chain reaction (PCR) was performed using an ABI PRISM 7300 Sequence Detection System instrument and software (Applied Biosystems) as described previously (Ghose et al., 2004, 2007; Shah et al., 2014). In short, each 25-μl reaction mixture contained 50–100 ng of cDNA, 300 nM forward primer, 300 nM reverse primer, 200 nM fluorogenic probe, and 15 μl of TaqMan Universal PCR Master Mix. PCR thermocycling parameters were 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. We extrapolated the quantitative expression values from standard curves, and these values were normalized to GAPDH. Data are represented as relative gene expression (normalized to vehicle control).

P450-Glo Activity Assay. HepG2 and HepaRG cells were cultured on white-walled, collagen-coated 96-well culture plates at a density of 1.0 × 10^5 cells/well. HepG2 and HepaRG cells were incubated for 24 and 72 hours, respectively, followed by pretreatment with DMSO (0.1%) or 30 μM SP for 30 minutes and treatment with 10 μM RIF or DMSO (0.1%). After treatment, cells were lysed, and luciferase enzymatic activity was measured using a P450-Glo commercial kit according to the manufacturer’s protocol (V9002; Promega). Specific CYP3A4 luminogenic substrate, luciferin-IPA, was added to the wells at a concentration of
3 μM and incubated at 37°C for 60 minutes. Light emission from the samples was detected by SpectraMax Microplate Reader/Luminometer, and net signal was calculated by subtracting background luminescence values.

**Immunoblotting.** HepG2 cells were seeded in six-well plates at 80% confluency. After 24 hours, at ~95% viability, cells were pretreated with vehicle (0.1% DMSO) or 30 μM SP for 30 minutes, followed by 10 μM RIF. Whole-cell, nuclear, and cytosolic extracts were prepared as described previously (Ghose et al., 2007, 2011), and the protein concentrations were determined using the bicinchoninic acid (BCA) assay according to the manufacturer’s protocol (Pierce, Rockford, IL). Immunoblotting was performed as described in previous publications (Moorthy et al., 2000; Jiang et al., 2004; Ghose et al., 2007, 2011). Briefly, equal amounts of protein (30 μg) were analyzed by SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were incubated with phospho-JNK, JNK, phospho-c-Jun, c-Jun, PXR, and lamin A/C primary antibodies overnight at 4°C, followed by incubation with goat anti-rabbit IgG-HRP secondary antibody or donkey anti-goat IgG secondary antibody for 60 minutes at room temperature. The membranes were then washed and incubated with HyGlo HRP antibody detection reagent (E2500; Denville Scientific, Rockford, IL). Immunoblotting was performed as described in previous publications (Moorthy et al., 2000; Jiang et al., 2004; Ghose et al., 2007, 2011). Briefly, equal amounts of protein (30 μg) were analyzed by SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were incubated with phospho-JNK, JNK, phospho-c-Jun, c-Jun, PXR, and lamin A/C primary antibodies overnight at 4°C, followed by incubation with goat anti-rabbit IgG-HRP secondary antibody or donkey anti-goat IgG secondary antibody for 60 minutes at room temperature. The membranes were then washed and incubated with HyGlo HRP antibody detection reagent (E2500; Denville Scientific, Rockford, IL). Immunoblotting was performed as described in previous publications (Moorthy et al., 2000; Jiang et al., 2004; Ghose et al., 2007, 2011).

**Chromatin Immunoprecipitation Assay.** ChIP assays were performed to assess specific binding of the PXR complex to the PXR response element on the CYP3A4 promoter as described in the manufacturer’s protocol (17-10466; EMD Millipore Inc.). HepG2 cells were seeded ~80%-90% confluency (1.0 x 10^6 cells/well) in a 150-mm culture dish containing 20 ml of growth media. Next day, HepG2 cells were pretreated with SP (30 μM) or DMSO (0.1%) for 30 minutes, followed by RIF (10 μM) for 24 hours. The cells were then crosslinked with 37% formaldehyde at room temperature for 10 minutes, washed twice with ice-cold phosphate-buffered saline, and collected in 1 ml of ice-cold phosphate-buffered saline. Cells were pelleted at 800g and digested by sonication (15 pulses, 20 seconds each, 30 seconds rest in between). The protein-DNA complexes were immunoprecipitated by using ChIP-grade anti-PXR antibody (SC-25381X; Santa Cruz). As a negative control, the beads were incubated with lysates without anti-PXR antibody. The chromatin was reverse crosslinked and eluted in 50 μl of elution buffer. DNA recovered from this assay was analyzed by endpoint PCR using primers for PXR binding site in the CYP3A4 promoter region (forward 5'-AGAACCCAGAACCCTTGAC-3' and reverse 5'-CTGGCTGTCGA GTTGGAAGAG-3'). PCR products were analyzed by agarose gel electrophoresis. Ten percent of the total cell lysate was used as "input." Eluted DNA was further analyzed by real-time PCR using the same primer mix as mentioned previously. ChIP DNA Ct values were normalized to input Ct values by subtracting the Ct value of the input (and dilution factor) from each sample according to method II of the manufacturer’s protocol. Estimated fold enrichment of the positive locus sequence in ChIP DNA over negative control is expressed as fold enrichment or fold induction.

**Statistical Analysis.** All data are presented as the mean ± S.D.s from at least three independent experiments (n = 3) unless otherwise specified. Differences between the groups were compared using Student’s unpaired two-tailed t test. One-way analysis of variance (ANOVA) with Dunnett’s post hoc test was applied to the data if more than two groups were analyzed. P value <0.05 was considered statistically significant.

**Results**

**Induction of CYP3A4 Luciferase Activity by PXR Was Mediated by JNK.** To determine the role of JNK in the induction of CYP3A4 reporter gene expression, we cotransfected HepG2 cells with plasmids expressing CYP3A4 reporter gene and PXR, followed by treatment with the PXR ligand RIF in the presence of JNK inhibitors. CYP3A4 reporter activity increased ~8-fold in the presence of 10 μM RIF compared with control (Fig. 1A). This CYP3A4 reporter induction by RIF was significantly attenuated by treatment with SP, indicating that JNK may be involved in regulating CYP3A4 induction by PXR. We observed that PD098059 (ERK inhibitor) cotreatment also inhibited CYP3A4 luciferase activity but not SB203580 (p38 inhibitor) (data not shown). In addition, we studied the effect of curcumin, a JNK pathway inhibitor of CYP3A4 reporter expression. As shown in Fig. 1A, 15 μM curcumin significantly attenuated RIF-mediated CYP3A4 induction by almost 50%. A significant difference was not observed between curcumin treatment alone and curcumin with RIF treatment. We further confirmed these findings by treating HepG2 cells with another PXR ligand, hyperforin, in the presence of the SP (Fig. 1B). Hyperforin is an active component of St. John’s wort and a potent activator of human PXR (Moore et al., 2000; Chen et al., 2004). CYP3A4 luciferase activity was induced by ~4-fold by 2 μM hyperforin at 24 hours, and this induction was significantly attenuated by SP treatment. SP had no effect on CYP3A4 luciferase activity in the absence of RIF or hyperforin (Fig. 1), indicating that JNK likely does not affect the basal expression of the CYP3A4 gene.

To confirm our results, we investigated the effect of simultaneous knockdown of JNK1 and JNK2 (using a siRNA that targets a homologous region present in both kinases) on CYP3A4 reporter gene induction (Fig. 2A). Knockdown of JNK1/2 expression reduced the ability of RIF to induce CYP3A4 luciferase activity in HepG2 cells, validating our previous data with pharmacologic inhibitors. No significant differences were found between control and JNK’siRNA-treated cells in the absence of RIF. The validity of the siRNAs was confirmed by the lack of JNK and phospho-JNK expression in JNK siRNA-treated cells (Fig. 2B). The fact that inhibition of JNK by pharmacologic inhibitors or siRNA attenuated CYP3A4 induction by two different PXR ligands (RIF and hyperforin) strongly indicates that PXR is likely regulated by JNK-dependent signaling mechanism. Furthermore, whereas CYP3A4 reporter expression in HepG2 cells without PXR plasmid was below the level of detection (data not shown), the same signal was significantly enhanced in PXR-transfected cells, suggesting a PXR-dependent effect.

**Induction of CYP3A4 Gene Expression by PXR Was in Part Mediated by JNK.** To determine the role of JNK in regulating endogenous CYP3A4 gene expression, HepG2 cells were treated with...
SP and RIF (Fig. 3). The cells were lysed to prepare mRNA, and CYP3A4 gene expression was analyzed. RIF treatment significantly induced CYP3A4 gene expression from 2 to 8 hours (~3–4.5 fold); the expression was lower at the 12-hour time point (~2-fold), although it was significantly induced compared with the control. We also observed ~2-fold CYP3A4 mRNA induction by RIF at 24 hours (data not shown). SP treatment significantly attenuated this induction. About 2-fold CYP3A4 mRNA induction by RIF was observed in HepG2 cells by other groups at longer time points (Novotna and Dvorak, 2014). These results were in agreement with our CYP3A4 luciferase activity data in transfected HepG2 cells. Since significant attenuation of CYP3A4 reporter gene activity was observed with ERK inhibitor, we also carried out gene expression studies using the ERK inhibitor PD098059 and found that PD098059 had no effect on RIF-induced CYP3A4 mRNA levels (data not shown).

**Induction of CYP3A4 Enzyme Activity by PXR was Mediated by JNK.** We performed P450-Glo assay to determine the role of JNK in PXR-mediated induction of CYP3A4 enzyme activity. As shown in Fig. 4A, treatment of HepG2 cells with RIF significantly induced CYP3A4 enzyme activity (~2.5 fold) compared with control, and SP attenuated this induction of CYP3A4 enzyme activity (as measured by the metabolism of the CYP3A4-specific substrate, luciferin IPA). To confirm our findings, we also conducted CYP3A4 activity assays in HepaRG cells, which are terminally differentiated hepatic cells derived from a human hepatic progenitor cell line that retains many characteristics of primary human hepatocytes (Parent et al., 2004). We observed a similar trend in HepaRG cells; RIF treatment significantly induced CYP3A4 enzyme activity from 4 to 12 hours; this induction was attenuated by the JNK inhibitor, SP (Fig. 4B). In these cell lines, we did not see any changes in DMSO-treated cells over time, and SP by itself did not have any effect on CYP3A4 activity (data not shown). Consistent with our gene expression results, SP does not affect CYP3A4 enzyme activity in the absence of RIF, indicating that JNK is likely not involved in regulating basal CYP3A4 activity.

**RIF Treatment Activated JNK In Vitro.** Since treatment with JNK inhibitors resulted in attenuation of PXR-mediated CYP3A4 reporter activity, gene expression, as well as enzyme activity, we determined the role of RIF in activation of JNK. Whole-cell extracts were prepared from treated HepG2 cells, and immunoblot analysis was carried out to determine phospho-JNK 1 and 2 protein expression. JNK exists in three distinct isoforms (JNK1–3). Although JNK1 and JNK2 genes are ubiquitously expressed, including in the liver, the JNK3 gene is selectively expressed in the brain, heart, and testis (Ip and Davis, 1998). Both phospho-JNK1 (p-JNK1) and phospho-JNK2 (p-JNK2) levels were increased by RIF treatment starting at 60 minutes, although this increase was attenuated in the presence of the JNK inhibitor SP (Fig. 5). At 2 and 4 hours, p-JNK protein levels increased compared with zero-time point, but this effect was not significant. In agreement with these findings, we found that the JNK substrate, c-Jun was phosphorylated after RIF treatment of 4 hours, and this phosphorylation was attenuated in the presence of SP (Fig. 5, C and D).

**PXR Nuclear Levels were Regulated by JNK.** Our results indicate that JNK likely affects PXR function; therefore, we determined the role of JNK in regulating PXR nuclear levels in RIF-treated HepG2 cells. As expected, PXR nuclear protein levels significantly increased from 4 to 24 hours in the presence of RIF (Fig. 6). Importantly, SP treatment attenuated RIF-mediated nuclear accumulation of PXR, indicating that PXR protein levels in the nucleus are regulated by JNK.

**PXR Binding to the CYP3A4 Promoter was Mediated by JNK.** Lastly, we performed in vitro ChIP assays to analyze whether decreased accumulation of PXR in the nucleus resulting from JNK inhibition impacts the binding of PXR to the CYP3A4 promoter. A commercially available ChIP-grade anti-PXR antibody was used to precipitate DNA-protein complexes. RIF treatment alone significantly increased the association of PXR with the regulatory regions of the CYP3A4 gene compared with control. Both our end point and quantitative RT-PCR data showed decreased binding of PXR to CYP3A4 promoter when JNK is inhibited (Fig. 7), supporting the hypothesis that JNK was required for optimum binding of PXR to its response elements on CYP3A4 gene. We
saw faint bands in cell lysates precipitated without anti-PXR antibody, which might be due to nonspecific binding. Input DNA from total cell lysate confirmed amplification of the CYP3A4 regulatory region targeted by specific primers.

**Discussion**

Induction of CYP3A4 enzyme expression/activity can have adverse effects on therapeutic outcome in patients. Therefore, the mechanism of CYP3A4 induction needs to be fully elucidated. This in vitro study demonstrates that CYP3A4 induction by PXR was mediated in part by a JNK-dependent mechanism. Research carried out in the last decade has shown that PXR-mediated gene expression is regulated not only by xenobiotics and endobiotics (Kliewer et al., 1998; Lehmann et al., 1998; Staudinger and Lichti, 2008; Pondugula et al., 2009b) but also by cellular signaling pathways. Post-translational modifications of PXR, especially direct phosphorylation, primarily led to an inhibition of its transcriptional activity (Wang et al., 2012); thereby downregulating Cyp3a expression. Our in vitro data, on the other hand, have shown that JNK is required for optimum induction of CYP3A4 via PXR. We provide additional evidence that PXR nuclear translocation, as well as binding of PXR to its response elements on CYP3A4 gene, is JNK-dependent.

To understand comprehensively the role of MAPKs in PXR-mediated CYP3A4 signaling, we investigated the role of all MAPKs by treating HepG2 cells with specific ERK 1/2 pathway inhibitor (PD098059), JNK 1/2/3 inhibitor (SP600125), and p38 inhibitor (SB203580). Specifically, SP600125, an anthrapyrazolone compound, is a potent inhibitor of all isoforms of JNK with an IC50 of 0.04 μM, but it exhibits greater than 300-fold selectivity against other MAPKs- ERK and p38 (IC50 > 10 μM) (Bennett et al., 2001). In our studies, whereas JNK and ERK 1/2 inhibition significantly attenuated PXR-mediated CYP3A4 luciferase activity, p38 inhibition showed no significant change. Curcumin, which can inhibit both JNK (IC50: 5 μM) and ERK (IC50: 20 μM) (Chen and Tan, 1998), also attenuated PXR-mediated CYP3A4 luciferase activity. MAPKs phosphorylate downstream kinases and nuclear factors, such as c-Jun, c-Fos, c-Myc, SP1, Elk1, etc. Since different MAPKs phosphor-ylate varying nuclear factors, it is possible that only nuclear factors activated by JNK and ERK might be involved in CYP3A4 regulation; however, the possibility of ERK being involved was eliminated from the results that the ERK inhibitor PD098059 had no effect on RIF-induced CYP3A4 mRNA and promoter activity by the VDR ligand 1,25(OH)2D3 was attenuated in the presence of a JNK inhibitor, whereas ERK or p-38 inhibition had no effect. SP is one of the most widely used and extensively studied ATP-competitive JNK inhibitors (Bogoyevitch and Arthur, 2008; Davies and Tournier, 2012; Zhang et al., 2012; Feng et al., 2013; Koch et al., 2015), and curcumin has been shown to inhibit JNK signaling pathways (Chen and Tan, 1998; Suh et al., 2007); however, these compounds can target additional pathways to affect CYP3A4 expression. For example, both SP and curcumin can activate aryl hydrocarbon receptor (AHR) (Cioloño et al., 1998; Bachleda and Dvorák, 2008; Dvorak et al., 2008; Mohammadi-Bardbori et al., 2012); recent
studies have shown that AHR activation decreases basal and RIF-induced CYP3A4 expression in HepaRG cells (Rasmussen et al., 2017). So it is possible that SP or curcumin can activate AHR to reduce CYP3A4 expression; however, these compounds did not affect basal CYP3A4 expression in our experiments. To address the potential issues associated with nonspecific effects of the pharmacologic inhibitors, we confirmed our results by siRNA experiments. Knockdown of JNK1/2 expression by siRNA also attenuated CYP3A4 induction by RIF in HepG2 cells. These data confirmed that JNK is indeed required for optimal activation of CYP3A4 as pharmacologic inhibition, as well as genetic knockdown of JNK1 and JNK2, attenuated its promoter activity significantly at 24 hours; however, the role of individual isoforms of JNK needs to be further investigated.

Additionally, we studied the effect of SP on RIF-mediated CYP3A4 mRNA and activity in HepG2 cells. HepG2 cells are frequently used for in vitro biotransformation assays (Westerink and Schoonen, 2007). Although HepG2 is a cheap and easy-to-use cell line, endogenous activity and expression of enzymes and NRs is relatively low in HepG2 cells compared with primary human hepatocytes (Xu et al., 2004). Despite this limitation, HepG2 cells are routinely used for induction studies, and previous reports have shown significant induction of CYP3A4 gene expression (~3- to 6-fold) as well as enzyme activity by RIF in these cells (Fascussi et al., 2001; Usui et al., 2003; Westerink and Schoonen, 2007). As an additional approach, we performed enzyme activity studies in HepaRG cells, which is a well established model for biotransformation applications (Gripon et al., 2002; Lambert et al., 2009; Anthérieu et al., 2010). In our data, attenuation of PXR-mediated induction of CYP3A4 enzyme activity in the presence of JNK inhibitor, irrespective of cell line, confirmed that JNK is required for induction of CYP3A4, and this is not a cell-line specific effect.

To understand the role of JNK in PXR regulation, we demonstrated that RIF activated JNK in HepG2 cells. Activation of PXR by RIF has previously been shown to increase phosphorylation of p38 MAPK; which was attributed to induction of GADD45β gene (Kodama and Negishi, 2011). GADD45β is an immediate to early response gene induced by various physiologic and environmental stressors, including cytokines and genotoxic stresses (Liebermann and Hoffman, 2008). Our data showing activation of JNK by RIF in HepG2 cells could potentially be mediated via similar targets of PXR. Alternatively, PXR may increase JNK expression; however, we did not detect any increase in total JNK protein levels in our experiments. Further studies to determine the mechanism of JNK activation by PXR are ongoing.

To determine the mechanism involved in JNK-mediated regulation of CYP3A4, we studied the role of JNK in regulating PXR nuclear translocation or its binding to CYP3A4 gene. PXR exists as a phosphoprotein in cells (Lichti-Kaiser et al., 2009a), and previous studies have shown that kinases decrease PXR transcription primarily either by strengthening PXR-corepressor interaction or weakening PXR-coactivator interactions. Recent studies have shown that activation of AMP-activated protein kinase and JNK by metformin lead to down-regulation of PXR expression and reduced expression of carboxylesterases (Shan et al., 2017). In contrast, our studies showed that JNK positively regulated PXR function without affecting its expression (data not shown). JNK may positively regulate PXR function by multiple mechanisms (Fig. 8), including the following: 1) JNK directly phosphorylates PXR and increases its nuclear translocation/binding to the CYP3A4 gene; 2) JNK phosphorylates cytoplasmic retention proteins associated with PXR and impacts its translocation; 3) JNK decreases PXR-corepressor binding; or 4) JNK increases PXR-coactivator binding. Although we did not study whether PXR is directly phosphorylated by JNK, we found that JNK is required for PXR nuclear translocation and binding to the CYP3A4 promoter, ultimately affecting PXR function. Using in silico computer-based analysis using PhosphoSitePlus, we found nine serine phosphorylation sites and seven threonine phosphorylation sites on PXR. Further studies to reveal their association with JNK are ongoing. Similar to our study, seven serine/threonine residues were also identified in human PXR protein; these residues are good potential substrates for an array of kinases.
including MAPKs (Lichti-Kaiser et al., 2009a). Using mass spectrometry analysis, some of these serine-threonine residues—such as S114, T133/135, S167, and S200 in PXR—were also found to be phosphorylated by cyclin-dependent kinase 2 (Elías et al., 2014).

In summary, in our in vitro data indicate that JNK, but not ERK or p38, is required for CYP3A4 gene activation by PXR. Further studies exploring the role of JNK on CYP3A4 induction in vivo will be critically relevant in studying PXR-mediated target gene expression. JNK is activated by various extracellular stimuli and thus regulates gene expression through phosphorylation of transcription/nuclear factors. Hence, elucidation of the contribution of JNK in the xenobiotic-induced expression of P450s may be instrumental in understanding the mechanism of induction of P450s, which can impact therapeutic outcome in patients undergoing treatment with multiple medications. Ultimately, understanding the role of JNK in induction of CYP3A4 could provide novel strategies to address concerns about loss of drug safety or efficacy resulting from alteration of expression and activity of the CYP3A4 enzyme.

Authorship Contributions

Participated in research design: Taneja, Moorhey, Ghose.
Conducted experiments: Taneja, Maturu, Chu.
Contributed new reagents or analytic tools: Moorhey, Ghose.
Performed data analysis: Taneja.
Wrote or contributed to the writing of the manuscript: Taneja, Moorhey, Ghose.

References

Bachleir B and Dvorak Z (2008) Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor. Gen Physiol Biophys 27:143–145.

Fig. 8. Potential roles of JNK in PXR-mediated induction of CYP3A4.


Address correspondence to: Dr. Romi Ghose, College of Pharmacy, Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 1441 Moursund Street, Houston, TX 77030. E-mail: rghose@central.uh.edu; or Dr. Bhagavatula Moorthy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates Avenue, Suite 530, Houston, TX 77030. E-mail: bmooorthy@bcm.tmc.edu